German radiopharma firm ITM has reported positive results from its phase 3 trial, potentially marking the first major success for radiopharmaceuticals in cancer treatment. The trial demonstrated that ITM-11, a targeted radiotherapy, can outperform traditional cancer treatments in patients suffering from inoperable, high-grade gastroenteropancreatic neuroendocrine tumors. The treatment combines a targeting molecule and a therapeutic radioactive isotope, significantly improving efficacy and safety.
Top 12 Client-Rated End-to-End Healthcare Cybersecurity Vendors Announced, Black Book Research
A survey encompassing 1,812 health organisations identified the top cybersecurity vendors in the healthcare industry. These vendors provide end-to-end security solutions that safeguard sensitive patient
